Form 4: Vigil Neuroscience Chief Medical Officer Receives Stock Option Grant

Petra Kaufmann, Chief Medical Officer of Vigil Neuroscience, Inc., was granted stock options to purchase 330,000 shares of common stock on March 18, 2024.

Summary

• Petra Kaufmann, the Chief Medical Officer of Vigil Neuroscience, Inc. (VIGL), filed a Form 4 with the SEC on March 20, 2024.
• The filing reports a transaction that occurred on March 18, 2024, where Kaufmann was granted stock options to purchase 330,000 shares of Vigil Neuroscience's common stock.
• The exercise price of the stock options is $3.14 per share.
• The options vest over time, with 25% vesting on March 18, 2025, and the remaining shares vesting monthly thereafter over 36 months.
• The stock option expires on March 18, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the executive's role and the company's future.

Positives

• The stock option grant aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing her to contribute to the company's success.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the stock option grant suggests an expectation of continued service and contribution from the Chief Medical Officer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is consistent with industry practices.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of 25% after one year followed by monthly vesting is a typical arrangement.
• The size of the grant (330,000 shares) would need to be compared to grants at peer companies to determine if it is above or below average.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to drive company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates